

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1600RXA

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 OCT 03 MATHDI removed from STN  
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America  
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of CAPLUS documents for use in third-party analysis and  
visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:45:31 ON 24 OCT 2005

$\Rightarrow$

## Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n) :

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

```
=> fil reg  
COST IN U.S. DOLLARS  
SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21
```

FILE 'REGISTRY' ENTERED AT 08:46:05 ON 24 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0  
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****  
*  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added, *  
* effective March 20, 2005. A new display format, IDERL, is now *  
* available and contains the CA role and document type information. *  
*  
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=>  
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10626356.str
```

The diagram illustrates a chemical structure with numbered nodes (1-21) and labeled atoms (O, N, Cb). Node 1 is at the top right, connected to node 2. Node 2 is connected to node 3, which is connected to node 4. Node 4 is connected to node 5, which is connected to node 6. Node 6 is connected to node 7, which is connected to node 8. Node 8 is connected to node 9, which is connected to node 10. Node 10 is connected to node 11, which is connected to node 12. Node 12 is connected to node 13, which is connected to node 14. Node 14 is connected to node 15, which is connected to node 16. Node 16 is connected to node 17, which is connected to node 18. Node 18 is connected to node 19, which is connected to node 20. Node 20 is connected to node 21. Atom 'O' is located near node 10. Atom 'N' is located near node 1. Atom 'Cb' is located near node 5.

O  
1  
5  
1

chain nodes :  
1 2 3 4 5 8 9 10

```

ring nodes :
15 16 17 18 19
chain bonds :
1-3 3-8 4-5 8-9 9-10
ring bonds :
15-16 15-19 16-17 17-18 18-19
exact/norm bonds :
1-3 3-8 4-5 8-9 9-10 15-16 15-19 16-17 17-18 18-19

```

G2 : SO2 , [\*1]

Match level :

1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 8:CLASS 9:CLASS 10:Atom 15:Atom  
16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS

Generic attributes :

1 :

Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : less than 2  
Type of Ring System : Monocyclic

Element Count :

### Node 1: Limited

N, N1

0,00

S, S0


C, C4

## L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

## L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 08:46:40 FILE 'REGISTRY

SAMPLE SCREEN SEARCH COMPLETED - 9711 TO ITERATE

20.6% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

### 3 ANSWERS

FULL FILE PROJECTIONS : ONLINE \*\*COMPLETE\*\*  
PROJECTED ITERATIONS : 188315 TO 200125  
PROJECTED ANSWERS : 63 TO 519

L2 3 SEA SSS SAM L1

```
=> s 11 full
FULL SEARCH INITIATED 08:46:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 192018 TO ITERATE
```

```
100.0% PROCESSED 192018 ITERATIONS
SEARCH TIME: 00.00.02
```

377 ANSWERS

L3 377 SEA SSS FUL L1

```
=> s 13 and caplus/lc
48312124 CAPLUS/LC
L4 368 L3 AND CAPLUS/LC
```

```
=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10626356.str
```

Hy G2 N0-10-8'y

17 18  
16 21  
15 19

1 2 3 8 9 10

O N Cb

```
O
|
1
      5
      |
      1
```

```
chain nodes :
1 2 3 4 5 8 9 10
ring nodes :
15 16 17 18 19
chain bonds :
1-3 3-8 4-5 8-9 9-10
ring bonds :
15-16 15-19 16-17 17-18 18-19
exact/norm bonds :
1-3 3-8 4-5 8-9 9-10 15-16 15-19 16-17 17-18 18-19
```

G2:SO2, [\*1]


```
Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 8:CLASS 9:CLASS 10:Atom 15:Atom
16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS
Generic attributes :
1:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic
```

```
Element Count :
Node 1: Limited
```

N,N1  
O,OO  
S,SO  
C,C4

L5 STRUCTURE UPLOADED

=> d  
L5 HAS NO ANSWERS  
L5 STR



O  
|  
|  
1  
G1  
G2 SO2, [@1]

Structure attributes must be viewed using STN Express query preparation.

=> s 15 subset=l3 full  
FULL SUBSET SEARCH INITIATED 08:52:42 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 300 TO ITERATE

100.0% PROCESSED 300 ITERATIONS 173 ANSWERS  
SEARCH TIME: 00.00.01

L6 173 SEA SUB=L3 SSS FUL L5

=> s 16 and caplus/lc  
48312124 CAPLUS/LC  
L7 173 L6 AND CAPLUS/LC

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	213.31	213.52

FILE 'CAPLUS' ENTERED AT 08:52:59 ON 24 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18  
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s 17  
L8                3 L7  
  
=> d ibib abs hitstr 1-3

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:158664 CAPLUS  
 DOCUMENT NUMBER: 142:261539  
 TITLE: Preparation of pyrrole-containing heterocyclic compounds as inhibitors of c-Met  
 INVENTOR(S): Aronov, Alex; Bandarage, Upul K.; Lauffer, David J.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA; Li, Pei; Tomlinson, Ronald C.  
 SOURCE: PCT Int. Appl., 61 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016920	A1	20050224	WO 2004-US26749	20040816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: EW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005101650	A1	20050512	US 2004-919774	20040816
PRIORITY APPN. INFO.:			US 2003-495535P	P 20030815

OTHER SOURCE(S): MARPAT 142:261539  
 GI




AB The title compds. I [Q is an alkylidene chain wherein one methylene unit of Q is replaced by CO, O, etc.; R1 = H, optionally substituted ring, etc.; R2 = optionally substituted 6-membered aryl ring having 0 - 5 nitrogens; n = 0 - 2; ring A = imidazole ring, etc.; R3 = CN, etc.] are prepared. Thus, 4-[5-(2,3-difluorophenyl)-isoxazol-4-yl]-1H-pyrrole-2-carboxylic acid (S-tert-butyl-2-ylmethyl)amide was prepared in a multistep process from 1-(1-benzensulfonyl)-1H-pyrrol-3-ylmethane. In an *in vitro* test for the inhibition of c-Met kinase, compds. of this invention showed Ki values of 1 to > 10  $\mu$ M.  
 IT 845867-57-4P 845867-58-5P 845867-59-6P  
 845867-61-0P 845867-62-1P 845867-63-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (Uses)  
 (prepn. of pyrrole-contg. heterocyclic compds. as inhibitors of c-Met)  
 RN 845867-57-4 CAPLUS  
 CN Azetidine, 1-[(4-[5-(2,3-difluorophenyl)-4-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 845867-58-5 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide,  
 4-[5-(2,3-difluorophenyl)-4-isoxazolyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 845867-59-6 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide,  
 4-[5-(2,3-difluorophenyl)-4-isoxazolyl]-N-[(2S)-tetrahydro-2-furanyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845867-61-0 CAPLUS  
 CN Pyrrolidine, 1-[(4-[3-(2,3-difluorophenyl)-4-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 845867-62-1 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide,  
 4-[3-(2,3-difluorophenyl)-4-isoxazolyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 845867-63-2 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide,  
 N-(cyclopentylmethyl)-4-[3-(2,3-difluorophenyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:906502 CAPLUS  
 DOCUMENT NUMBER: 140:111220  
 TITLE: Solid-Phase Synthesis of an Isoxazolinopyrrole  
 Library  
 AUTHOR(S): Hwang, Sung Hee; Olmstead, Marilyn M.; Kurth, Mark J.  
 CORPORATE SOURCE: Department of Chemistry, University of California, Davis, CA, 95616-5295, USA  
 SOURCE: Journal of Combinatorial Chemistry (2004), 6(1), 142-148  
 CODEN: JCHFF; ISSN: 1520-4766  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:111220  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB A four-step solid-phase synthesis of isoxazolinopyrroles, e.g., I, that employs an acid-labile 2-(4-formyl-3-methoxyphenyl)ethyl polystyrene HL resin is reported. Resin-bound vinyl sulfone II (R1 = PhCH<sub>2</sub>, 2-furanylmethyl, Me<sub>2</sub>CHCH<sub>2</sub>, MeOCH<sub>2</sub>; X = resin) is obtained by DIC coupling of resin-bound amines with acid III (R2 = H, Me), which was in turn synthesized in solution phase by a regioselective nitrile oxide, 1,3-dipolar cycloaddn. The resin-bound pyrrole, e.g., IV, was synthesized

on solid phase by pyrrole annulation with various isocyano derivs. and potassium t-butoxide in which the sulfone  $\alpha$ -anion generated by Michael addition gives the desired pyrrole through internal condensation followed by a sigmatropic [1,5]-hydrogen shift. The resulting isoxazolinopyrroles were released from resin by 10% TFA in moderate to excellent overall yields.


IT 646064-11-1P 646064-12-2P 646064-13-3P  
 646064-14-4P 646064-18-8P 646064-19-9P  
 646064-20-2P 646064-21-3P 646064-22-4P  
 646064-23-5P 646064-24-6P 646064-25-7P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
 (preparation of an isoxazolinopyrrole library via coupling of resin-bound amines with sulfonylvinylisoxazolyl benzoic acids followed by pyrrole annulation with various isocyano derivs. and subsequent cleavage from the resin)


RN 646064-11-1 CAPLUS  
 CN Benzamide,  
 4-[4,5-dihydro-5-methyl-5-(4-(phenylsulfonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 646064-12-2 CAPLUS  
CN Benzamide,  
4-[4,5-dihydro-5-methyl-5-[4-(phenylsulfonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-furanyl methyl)- (9CI) (CA INDEX NAME)




RN 646064-13-3 CAPLUS  
CN Benzamide,  
4-[4,5-dihydro-5-methyl-5-[4-(phenylsulfonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 646064-14-4 CAPLUS  
CN Benzamide,  
4-[4,5-dihydro-5-methyl-5-[4-(phenylsulfonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 646064-18-8 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-(1-piperidinyl carbonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 646064-19-9 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-(1-piperidinyl carbonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-furanyl methyl)- (9CI) (CA INDEX NAME)




RN 646064-20-2 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-(1-piperidinyl carbonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 646064-21-3 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-(1-piperidinyl carbonyl)-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 646064-22-4 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 646064-23-5 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-furanyl methyl)- (9CI) (CA INDEX NAME)



RN 646064-24-6 CAPLUS  
CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 646064-25-7 CAPLUS  
CN Benzamide, 4-[4-(4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methoxyethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002022610	A1	20020321	WO 2001-US28790	20010914	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	CA 2422376	AA	20020321	CA 2001-2422376	20010914
AU 2001090940	A5	20020326	AU 2001-90940	20010914	
US 2002177618	A1	20021128	US 2001-953120	20010914	
US 6495582	B2	20021217			
EP 1317453	A1	20030611	EP 2001-971002	20010914	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	T2	20040325	JP 2002-526863	20010914	
JP 200405119	A	20040428	ZA 2003-1696	20010914	
ZA 2003001696	A	20041029	NZ 2001-525016	20010914	
NZ 525016	A	20031016	US 2002-272622	20021015	
US 2003195241	A1	20031118	US 6649640		
US 6649640	B2	20031118	NO 2003-1192	20030314	
NO 2003001192	A	20030513	US 2003-626356	20030724	
US 2005090536	A1	20050428	P 20000915		
PRIORITY APPLN. INFO.:			US 2000-232956P	P 20000915	
			US 2001-953120	A3 20010914	
			WO 2001-US28790	W 20010914	

OTHER SOURCE(S): MARPAT 136:247569  
AB Title compds., e.g., Ph2122CONMe2 (Z1 = isoxazole-4,5-diyl, Z2 = pyrrole-4,2-diyl) were prepared Data for biol. activity of title compds. were given.


IT 404570-75-8P 404570-76-9P 404570-77-0P  
404570-78-1P 404570-79-2P 404570-80-5P  
404570-81-6P 404570-82-7P 404570-83-8P  
404570-84-9P 404570-85-0P 404570-86-1P  
404570-87-2P 404570-88-3P 404570-89-4P  
404570-90-7P 404570-91-8P 404570-92-9P  
404570-93-0P 404570-94-1P 404570-95-2P  
404570-96-3P 404570-97-4P 404570-98-5P

404570-09-6P 404571-00-3P 404571-01-3P  
404571-02-4P 404571-03-5P 404571-04-6P  
404571-05-7P 404571-06-8P 404571-07-9P  
404571-08-0P 404571-09-1P 404571-10-4P  
404571-11-5P 404571-12-6P 404571-13-7P  
404571-14-8P 404571-15-9P 404571-16-0P  
404571-17-1P 404571-18-2P 404571-19-3P  
404571-20-6P 404571-21-7P 404571-22-8P  
404571-23-9P 404571-24-0P 404571-25-1P  
404571-26-2P 404571-27-3P 404571-28-4P  
404571-29-5P 404571-30-6P 404571-31-7P  
404571-32-0P 404571-33-1P 404571-34-2P  
404571-35-3P 404571-36-4P 404571-37-5P  
404571-38-6P 404571-39-7P 404571-40-0P  
404571-41-1P 404571-42-2P 404571-43-3P  
404571-44-4P 404571-45-5P 404571-46-6P  
404571-53-5P 404571-54-6P 404571-55-7P  
404571-56-8P 404571-57-9P 404571-58-0P  
404571-59-1P 404571-60-4P 404571-61-5P  
404571-62-6P 404571-63-7P 404571-64-8P  
404571-65-9P 404571-66-0P 404571-67-1P  
404571-68-2P 404571-69-3P 404571-70-6P  
404571-71-7P 404571-72-8P 404571-73-9P  
404571-74-0P 404571-75-1P 404571-76-2P  
404571-77-3P 404571-78-4P 404571-79-5P  
404571-80-6P 404571-81-7P 404571-82-0P  
404571-83-1P 404571-84-2P 404571-85-3P  
404571-86-4P 404571-87-5P 404571-88-6P  
404571-89-7P 404571-90-0P 404571-91-1P  
404571-92-2P 404571-93-3P 404571-95-5P  
404571-96-6P 404571-97-7P 404571-98-8P  
404572-00-5P 404572-00-5P 404572-01-6P  
404572-02-7P 404572-03-8P 404572-04-9P  
404572-05-0P 404572-06-1P 404572-07-2P  
404572-08-3P 404572-09-4P 404572-10-7P  
404572-09-4P 404572-10-9P 404572-12-0P  
404572-14-1P 404572-15-2P 404572-16-3P  
404572-17-4P 404572-18-5P 404572-20-9P  
404572-21-0P 404572-22-1P 404572-23-2P  
404572-24-3P 404572-25-4P 404572-26-5P  
404572-28-7P 404572-29-8P 404572-30-1P  
404572-31-2P 404572-32-3P 404572-33-4P  
404572-35-6P 404572-36-7P 404572-38-9P  
404572-39-0P 404572-40-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of isoxazolylpyrrole-2-carboxamides as ERK and AKT protein kinase inhibitors)

RN 404570-75-8 CAPLUS


CN Morpholine, 4-[(4-(2-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404570-76-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(4-methoxyphenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-77-0 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-fluorophenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-78-1 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-methoxyphenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 404570-79-2 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 404570-80-5 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-81-6 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-82-7 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 404570-83-8 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-methoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-84-9 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-fluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-85-0 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 404570-86-1 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-87-2 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-88-3 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 404570-89-4 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-methoxyphenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-90-7 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-fluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-91-8 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-92-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]-(9CI) (CA INDEX NAME)




RN 404570-93-0 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN- 404570-94-1 CAPLUS  
CN- 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl] - (9CI) (CA INDEX NAME)




RN 404570-95-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[4-(4-fluorophenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404570-96-3 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-methoxyphenyl)-5-isoxazolyl) (9CI) (CA INDEX NAME)




RN 404570-97-4 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-(3-fluorophenyl)-5-isoxazolyl)-(9CI) (CA INDEX NAME)




RN 404570-98-5 CAPILUS  
CN 1H-Pyrrole-2-carboxamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-4-[4-(3-methoxyphenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404570-99-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-00-2 CAPLUS  
CN 11-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyridinyl)methyl] - (9CI) (CA INDEX NAME)




RN 404571-01-3 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrrolidinyl)methyl] - (SCI) (CA INDEX NAME)




RN 404571-02-4 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-[(1-  
methyl-2-pyrazinyl)dimethylamino]- (C<sub>22</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>2</sub>S<sub>2</sub>)




RN 404571-03-5 CAPLUS  
CN Morpholine, 4-[(4-[4-(3-methoxyphenyl)-5-isoxazolyl]-1H-pyrrrol-2-




RN 404571-04-6 CAPLUS  
CN Morpholine, 4-[(4-[2,5-dimethoxyphenyl]-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-05-7 CAPLUS  
CN Morpholine, 4-[(4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-06-8 CAPLUS  
CN Morpholine, 4-[(4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-09-1 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)



RN 404571-11-5 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-12-6 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-13-7 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)


RN 404571-07-9 CAPLUS  
CN Piperazine, 1-[(4-[4-(4-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-08-0 CAPLUS  
CN Piperazine, 1-[(4-[4-(4-methoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-09-1 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-10-4 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-methoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-11-5 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-12-6 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-13-7 CAPLUS  
CN Piperazine, 1-[(4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-14-8 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-15-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-16-0 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-(tetrahydro-2-furanyl)methyl- (9CI) (CA INDEX NAME)




RN 404571-17-1 CAPLUS  
CN 1H-Pyrrole-2-carboxamide,  
4-[4-(3-chlorophenyl)-5-isoxazolyl]-N-[(1-ethyl-  
2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-18-2 CAPLUS  
CN Piperazine, 1-[4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-  
yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-19-3 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-(4-(4-chlorophenyl)-5-isoxazolyl)-N-(4-  
pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-20-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-chlorophenyl)-5-isoxazolyl]-N-(3-  
pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-21-7 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-chlorophenyl)-5-isoxazolyl]-N-  
[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-22-8 CAPLUS  
CN 1H-Pyrrole-2-carboxamide,  
4-[4-(4-chlorophenyl)-5-isoxazolyl]-N-[(1-ethyl-  
2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-23-9 CAPLUS  
CN Morpholine, 4-[4-(4-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-  
yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-24-0 CAPLUS  
CN Piperazine, 1-[4-(4-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-  
yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-25-1 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dichlorophenyl)-5-isoxazolyl]-N-(3-  
pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-26-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dichlorophenyl)-5-isoxazolyl]-N-[(1-  
ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-27-3 CAPLUS  
CN Morpholine, 4-[4-(4-(3,4-dichlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-  
yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-28-4 CAPLUS  
CN Piperazine, 1-[4-(4-(3,4-dichlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-  
yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-29-5 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-30-8 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-31-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-




RN 404571-32-0 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-(1-ethyl-2-pyrrolidinyl)methyl)- (9CI) (CA INDEX NAME)




RN 404571-33-1 CAPLUS  
CN Morpholine, 4-[4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-34-2 CAPLUS  
CN Piperazine, 1-[4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-35-3 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-36-4 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-37-5 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-38-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-chloro-4-fluorophenyl)-5-isoxazolyl]-N-(1-ethyl-2-pyrrolidinyl)methyl)- (9CI) (CA INDEX NAME)




RN 404571-39-7 CAPLUS  
CN Morpholine, 4-[4-(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-40-0 CAPLUS  
CN Piperazine, 1-[4-(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl-4-methyl- (9CI) (CA INDEX NAME)





RN 404571-41-1 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-42-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 404571-43-3 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-(tetrahydro-2-furanyl)methyl)- (9CI) (CA INDEX NAME)




RN 404571-54-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-55-7 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-(tetrahydro-2-furanyl)methyl)- (9CI) (CA INDEX NAME)


RN 404571-44-4 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-45-5 CAPLUS  
CN Morpholine, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-46-6 CAPLUS  
CN Piperazine, 1-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-53-5 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-56-8 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-57-9 CAPLUS  
CN Morpholine, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-58-0 CAPLUS  
CN Piperazine, 1-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-59-1 CAPLUS  
CN Morpholine, 4-[(4-[4-(4-(aminosulfonyl)-3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-60-4 CAPLUS  
CN Morpholine, 4-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-61-5 CAPLUS  
CN Piperazine, 1-(2-fluorophenyl)-4-[(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-62-6 CAPLUS  
CN Piperazine, 1-phenyl-4-[(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-63-7 CAPLUS  
CN Piperazine, 1-[(4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 404571-64-8 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404571-65-9 CAPLUS  
CN Isoquinoline, 2-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 404571-66-0 CAPLUS  
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(4-[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-67-1 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-68-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-69-3 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404571-70-6 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-71-7 CAPLUS  
CN Isoquinoline, 2-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 404571-72-8 CAPLUS  
CN 3-Piperidinol, 1-[(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-73-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-74-1 CAPLUS  
CN 3-Piperidinol, 1-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-75-1 CAPLUS  
CN Piperazine, 1-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 404571-76-2 CAPLUS  
CN Piperazine, 1-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 404571-77-3 CAPLUS  
CN 2-Piperideineethanol, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-78-4 CAPLUS  
CN 1,4'-Bipiperidine, 1'-(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl- (9CI) (CA INDEX NAME)




RN 404571-79-5 CAPLUS  
CN 2-Piperideineethanol, 1-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-80-8 CAPLUS  
CN 2-Piperideineethanol, 1-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 404571-81-9 CAPLUS  
CN Piperazine, 1-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404571-82-0 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)




RN 404571-83-1 CAPLUS  
CN Piperazine, 1-[(4-(4-methoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404571-84-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-(4-phenyl-5-isoxazolyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-85-3 CAPLUS  
CN Morpholine, 4-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-86-4 CAPLUS  
CN Pyrrolidine, 1-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-87-5 CAPLUS  
CN Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-88-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-89-7 CAPLUS  
CN Pyrrolidine, 1-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-90-0 CAPLUS  
CN Piperazine, 1-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404571-91-1 CAPLUS  
CN Morpholine, 4-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-92-2 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-methylphenyl)-5-isoxazolyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-93-3 CAPLUS  
CN Pyrrolidine, 1-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-95-5 CAPLUS  
CN Pyrrolidine, 1-[(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-96-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-97-7 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 404571-98-8 CAPLUS  
CN Pyrrolidine, 1-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-99-9 CAPLUS  
CN Pyridine, 1-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 404572-00-5 CAPLUS  
CN Piperazine, 1-[(4-[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404572-01-6 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-methyl-4-(4-phenyl-5-isoxazolyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404572-02-7 CAPLUS  
CN Piperazine, 1-(4-methoxyphenyl)-4-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-03-8 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, 4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404572-04-9 CAPLUS  
CN Pyridine, 1-[(4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl)carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 404572-05-0 CAPLUS  
CN Piperazine, 1-[(4-(3-methoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404572-06-1 CAPLUS  
CN 1H,1,4-Diazepine, hexahydro-1-methyl-4-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl- (9CI) (CA INDEX NAME)



RN 404572-07-2 CAPLUS  
CN 2-Piperidinemethanol, 1-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-08-3 CAPLUS  
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 404572-09-4 CAPLUS

CN Piperazine, 1-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 404572-10-7 CAPLUS

CN Piperazine, 1-acetyl-4-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-11-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-methyl-4-(4-(3-methylphenyl)-5-isoxazolyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 404572-12-9 CAPLUS


CN 2-Piperidinemethanol, 1-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 404572-16-3 CAPLUS

CN 1H-1,4-Diazepine, 1-[(4-(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 404572-17-4 CAPLUS

CN 1H-1,4-Diazepine, 1-[(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 404572-18-5 CAPLUS


CN 3-Piperidinol, 1-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 404572-20-9 CAPLUS


CN Piperazine, 1-acetyl-4-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 404572-13-0 CAPLUS

CN 2-Piperidinemethanol, 1-[(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-14-1 CAPLUS

CN 2-Piperidineethanol, 1-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 404572-15-2 CAPLUS


CN 2-Piperidineethanol, 1-[(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 404572-21-0 CAPLUS

CN Piperazine, 1-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-22-1 CAPLUS

CN 1-Piperazineethanol, 4-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-23-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl)- (9CI) (CA INDEX NAME)




RN 404572-24-3 CAPLUS

CN Pyridine,  
4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)


RN 404572-25-4 CAPLUS

CN Piperazine, 1-acetyl-4-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-26-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 404572-28-7 CAPLUS

CN Piperazine, 1-acetyl-4-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-29-8 CAPLUS

CN Isoquinoline,  
2-[(4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

RN 404572-30-1 CAPLUS


CN 1H-Pyrrole-2-carboxamide, N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-4-(4-phenyl-5-isoxazolyl), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 404572-31-2 CAPLUS

CN 3-Piperidinol, 1-[(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-32-3 CAPLUS

CN Piperazine, 1-[(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 404572-33-4 CAPLUS

CN 1-Piperazineethanol, 4-[(4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-35-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-methyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 404572-36-7 CAPLUS


CN 2-Piperidineethanol, 1-[(4-(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-38-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-methyl-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 404572-39-0 CAPLUS  
CN 1,4'-Bipiperidine, 1'-(14-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrrol-2-yl)carbonyl- (9CI) (CA INDEX NAME)



RN 404572-40-3 CAPLUS  
CN 4-Piperidinol, 1-[(4-(4-phenyl-5-isoxazolyl)-1H-pyrrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

=> fil reg			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	15.27	228.79	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-2.19	-2.19	

FILE 'REGISTRY' ENTERED AT 08:53:22 ON 24 OCT 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0  
 DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*  
 \*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 08:45:31 ON 24 OCT 2005)

FILE 'REGISTRY' ENTERED AT 08:46:05 ON 24 OCT 2005

L1	STRUCTURE uploaded
L2	3 S L1
L3	377 S L1 FULL
L4	368 S L3 AND CAPLUS/LC
L5	STRUCTURE uploaded
L6	173 S L5 FULL SUB=L3
L7	173 S L6 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 08:52:59 ON 24 OCT 2005

L8

3 S L7

FILE 'REGISTRY' ENTERED AT 08:53:22 ON 24 OCT 2005

=> s 14 not 17  
L9 195 L4 NOT L7

=> fil caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
0.43 229.22  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
CA SUBSCRIBER PRICE ENTRY SESSION  
0.00 -2.19

FILE 'CAPLUS' ENTERED AT 08:53:33 ON 24 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18  
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 19  
L10 60 L9

=> d ibib abs hitstr 1-3 and 57-60  
'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE  
PATs ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end


=> d ibib abs hitstr 1-3

L10 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:962251 CAPLUS  
 DOCUMENT NUMBER: 143:266955  
 TITLE: Synthesis of polyheterocyclic compounds as metabotropic glutamate receptor antagonists  
 INVENTOR(S): Arora, Jala; Edwards, Louise; Isaac, Methvin; Kers, Annika; Staaf, Karin; Slassi, Abdelmalik; Stefanac, Tomislav; Wensbo, David; Xin, Tao; Holm, Bjorn  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 99 pp.  
 CODEN: PIIXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080386	A1	20050901	WO 2005-US5216	20050217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		US 2004-545292P		P 20040218

PRIORITY APPLN. INFO.:


G1



L10 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 863647-39-6 CAPLUS  
 CN Pyridine, 3-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-methyl-4H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)




RN 863647-40-9 CAPLUS  
 CN Pyridine, 4-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The authors prepared polyheterocyclic compds. I (T = (hetero)aryl, W is attached to C atom on T, W = (R1)m, R1 = OH, halo, NO2, OC1-C6-alkylhalo, Cl-C6-alkyl, C2-C6-alkenyl, Cl-C6-alkylhalo, Cl-C6-alkyl(CO)R5, SO3R5, etc., R5 = H, Cl-C6-alkyl, C3-C7-cycloalkyl, aryl, m = 0-4; Y = (R3)p, z = (R2)n, R2, R3 = OH, CO-C6-alkylcyano, O, NR5, NOR5, halo, OC1-C4-alkyl, etc., n, p = 0-4; X1 = N, NR4, CR4, R4 = H, OH, Cl-C6-alkyl, CO-C6-alkylcyano, (SO)CO-C4-alkyl, etc.; X2 = C, N: X3 = CR4, N, O; X4 = CR4, N, NR4, O; X5 = bond, CR4R8, NR4, O, S, SO, SO2, R8 = undefined; X6 = CR4, N; X7 = C, N; Q = heterocycloalkyl, heterocyclic] for use in treating mGluR5-mediated disorders such as for treating chronic and acute pain disorders. Thus, 4-[(dimethylaminoethoxybenzoic acid Me ester II to give triazolylphenoxy di-Me amine III.


IT 863647-37-42 863647-39-6P  
 863647-40-9P 863647-41-0P 863647-42-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of polyheterocyclic compds., their metabotropic glutamate receptor antagonist activity, and use in treating mGluR5 mediated disorders)

RN 863647-37-4 CAPLUS  
 CN Morpholine,  
 4-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 863647-38-5 CAPLUS  
 CN Morpholine,  
 4-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-methyl-4H-1,2,4-triazol-3-yl]-2-pyridinyl- (9CI) (CA INDEX NAME)


L10 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 863647-41-0 CAPLUS  
 CN Pyridine, 4-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-methyl-4H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)




RN 863647-42-1 CAPLUS  
 CN Pyridine, 3-[5-{2-[5-(3-chlorophenyl)-3-isoxazolyl]-1-pyrrolidinyl}-4-cyclopropyl-4H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)




IT 863647-31-0P 863647-32-PP 863647-33-OP  
863647-34-1P 863647-35-2P 863647-36-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of polyheterocyclic compds., their metabotropic glutamate receptor antagonist activity, and use in treating mGluR5 mediated disorders)


RN 863647-31-8 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 2-[5-(3-chlorophenyl)-3-isoxazolyl]-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)




RN 863647-32-9 CAPLUS  
CN Isoxazole, 5-(3-chlorophenyl)-3-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 863647-33-0 CAPLUS  
CN 1-Pyrrolidinecarbothioamide, 2-(5-(3-chlorophenyl)-3-isoxazolyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 863647-34-1 CAPLUS  
CN 1-Pyrrolidinecarbothioamide, 2-(5-(3-chlorophenyl)-3-isoxazolyl)-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 863647-35-2 CAPLUS  
CN 1-Pyrrolidinecarboximidothioic acid, 2-(5-(3-chlorophenyl)-3-isoxazolyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 863647-36-3 CAPLUS  
CN 1-Pyrrolidinecarboximidothioic acid, 2-(5-(3-chlorophenyl)-3-isoxazolyl)-N-cyclopropyl-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L10 ANSWER 2 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:582509 CAPLUS  
DOCUMENT NUMBER: 143:115522  
TITLE: A method for preparing 3,4-diphenyl-substituted isoxazole derivatives such as valdecoxib, parecoxib, and their intermediates  
INVENTOR(S): Sundaram, Venkataraman; Bhimireddy, Anuradha; Eswaraiah, Sajja; Goverdhan, Gilla; Purandhar, Koilkonda; Rajendra, Surasani; Raju, Nadimpally Satyavaraha; Reddy, Anumula Raghupathi; Reddy, Lekkala Amarnath; Reddy, Emani Srinivasa; Reddy, Padi Prathap; Sampath, Alla; Sravanti, Veena Reddy's Laboratories Ltd., India; Reddy's Laboratories, Inc.  
PATENT ASSIGNEE(S): Eur. Pat. Appl., 15 pp.  
SOURCE: CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1550658	A1	20050706	EP 2004-258181	20041230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2005182113	A1	20050818	US 2004-25855	20041229
CA 2491332	AA	20050630	CA 2004-2491332	20041230
PRIORITY APPLN. INFO.:			IN 2003-CH1063	A 20031230
			US 2004-591799P	P 20040728
			US 2004-637782P	P 20041221

OTHER SOURCE(S): MARPAT 143:115522  
GI




AB The invention relates to a process for preparing 3,4-diphenyl-substituted isoxazole derivs. of formula I [wherein: X is H, SO2-alkyl, SO2NH2, or alkanoylamino-SO2] such as valdecoxib, parecoxib, and their intermediates. For instance, 3,4-diphenyl-5-methylisoxazole (I, X is absent) was prepared via one-pot cyclocondensation of benzonitrile oxide with 1-(1-methyl-2-phenylethynyl)pyrrolidine and subsequent pyrrolidine removal.

L10 ANSWER 2 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 of the obtained 3,4-diphenyl-5-methyl-5-pyrrolidinylisoxazoline with a yield of 22.2%.

IT 857259-65-5P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (method for preparing 3,4-diphenyl-substituted isoxazole derivs. such as valdecoxib, parecoxib, and their intermediates)

RN 857259-65-5 CAPLUS

CN Isoxazole, 4,5-dihydro-5-methyl-3,4-diphenyl-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 ACCESSION NUMBER: 2005:395305 CAPLUS  
 DOCUMENT NUMBER: 142:463737  
 TITLE: Preparation of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer  
 INVENTOR(S): Nowak, Thorsten; Thomas, Andrew Peter  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 272 pp.  
 CODEN: PIXKD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040159	A1	20050506	WO 2004-GB4307	20041011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			GB 2003-24335	A 20031017
			GB 2004-12194	A 20040602

OTHER SOURCE(S): MARPAT 142:463737  
 GI




L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


AB The title compds. I [R1 = CF3, alkyl, cycloalkyl, (cycloalkyl)alkyl; R2 = H, halo, CF3; R3 = H, OH, halo, etc.; NQ1 = N-linked saturated monocyclic 5-6 membered ring containing one N heteroatom and optionally comprising one or more addnl. ring heteroatoms selected from N, O and S; Q2 = (un)substituted 5-6 membered heteroaryl comprising at least one ring heteroatom selected from N, O and S], useful in modulating insulin-like growth factor 1 receptor activity in a warm blooded animal such as man, were prepared. Thus, reacting 2,5-dichloro-4-(5-methyl-1H-pyrazol-3-yl)pyrimidines with 2-[3-(pyridin-2-yl)isoxazol-5-yl]pyrrolidine (preparation given) in the presence EtN(iso-Pr)2 in n-hexanol afforded

II. HCl.  
 The compds. I of the examples were found to have an IC50 of <100 μM in IGF-1R kinase assay. The pharmaceutical composition comprising the compound I is disclosed.  
 IT 851432-02-5P 851432-03-6P 851432-09-2P  
 851432-10-5P 851433-96-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer)

RN 851432-02-5 CAPLUS  
 CN 4-Pyrimidinamine, 5-chloro-2-(2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 RN 851432-03-6 CAPLUS  
 CN 4-Pyrimidinamine, 5-chloro-2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 RN 851432-09-2 CAPLUS

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 RN 851432-10-5 CAPLUS  
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-methyl-1H-pyrazol-3-yl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 RN 851433-96-0 CAPLUS  
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-methyl-1H-pyrazol-3-yl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
 IT 851434-03-0P, 2-(3-Cyclopropylisoxazol-5-yl)pyrrolidine  
 851434-90-7P 851434-91-0P, 2-[2-(3-Cyclopropylisoxazol-5-yl)pyrrolidin-1-yl]-4-hydroxy-6-methoxymethylpyrimidine

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 851434-92-9P, 4-Chloro-2-[2-(3-cyclopropylisoxazol-5-yl)pyrrolidin-1-yl]-6-methoxymethylpyrimidine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prep. of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer)  
 RN 851434-83-8 CAPLUS  
 CN Isoxazole, 3-cyclopropyl-5-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 851434-90-7 CAPLUS  
 CN 1-Pyrrolidinecarboximidamide, 2-(3-cyclopropyl-5-isoxazolyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 851434-89-4  
 CMF C11 H16 N4 O




CM 2  
 CRN 7664-93-9  
 CMF H2 O4 S

RN 851434-91-8 CAPLUS  
 CN 4(1H)-Pyrimidinone, 2-(2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 851434-92-9 CAPLUS  
 CN Pyrimidine, 4-chloro-2-(2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

=> d ibib abs hitstr 57-60


L10 ANSWER 57 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1966:438483 CAPLUS  
 DOCUMENT NUMBER: 65:38483  
 ORIGINAL REFERENCE NO.: 65:7160g-h, 7161a-d  
 TITLE: Convenient synthesis of indoxazenes  
 AUTHOR(S): Bianchi, Giorgio; Frati, Enzo  
 CORPORATE SOURCE: Univ. Pavia  
 SOURCE: Gazzetta Chimica Italiana (1966), 96(5), 559-65  
 CODEN: GCITA9; ISSN: 0016-5603  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Italian  
 GI For diagram(s), see printed CA Issue.  
 AB 3-Aryltetrahydroindoxazenes, obtained by the condensation of the appropriate nitrile oxides with suitable cyclohexanone enamines and subsequent treatment with acids, were dehydrogenated with N-bromosuccinimide to the corresponding 3-arylindoxazenes (I). 3-Phenylnaphtho[2,1-d]isoxazole (II) and the [1,2-d]-isomer were also prepared in this manner. α-Tetralone condensed with pyrrolidine yielded 18% 1-pyrroliodino-3,4-dihydropthalene, b.p. 25, 102-4°. m-O2NC6H4CN(O), m. 82-3°, was prepared from m-O2NC6H4C(=O)OH with 1 mole equivalent NaOEt. The appropriate nitrile oxide and enamine (equimolar amounts) in Et2O refluxed 2 hrs. yielded the corresponding IV (X = morpholinol, 91-2%; iso-Pr2O, 264, 4.10; IV (Ar = m-O2NC6H4, R = H, X = pyrrolidino), 96-7° (EtOH), 260, 4.26; IV (Ar = Ph, R = Me, X = pyrrolidino), 88-9° (petroleum ether), 264, 4.08; VI (X = pyrrolidino) (VII), 148° (MeOH), 264, 4.16; VIII (X = morpholinol) (IX), 241° (AcOEt or PhNO2), 256, 4.02. The appropriate IV and VII and IX refluxed 1-2 hrs. with 10% H2SO4 yielded 50-90% of the following compds. (same data given): IVa (Ar = m-O2NC6H4, R = H), 126° (EtOH), 230, 4.30; VIa (Ar = Ph, R = Me), 60° (MeOH), 240, 4.09; X, 112° (MeOH), 222 (285, 300), 4.39 (4.22, 4.12); XI, 88° (MeOH), 257, 4.04. The appropriate IVa and X and XI (0.02 mole) in CC14 treated with 0.04, 0.02, and 0.02 mole equivs. N-bromosuccinimide and a trace [Me2C(CN)N]2, refluxed, treated with AcONa in the presence of AcOH or with KOH-MeOH yielded the following compds. (Yield and m.p. given):

I (Ar = Ph, R = H), 53, 82.5°; I (Ar = m-O2NC6H4, R = H) (XII), 90, 171-2° (C6H6); I (Ar = Ph, R = Me), --, 92-3° (MeOH); II, 67, 133° (MeOH); III, 92, 62-3° (petroleum ether). In the preparation of XII, the intermediate yellow 3-(3-nitrophenyl)-4,7-dibromo-4,5,6,7-tetrahydroindoxazene, m. 154-5°, could be isolated in 70% yield. III in 95% EtOH hydrogenated over Raney Ni, and the crude product heated 20 min. with 50% H2SO4 yielded 91% yellow 1-benzoyl-2-naphthol, m. 66° (petroleum ether).  
 IT 7007-73-0, Naphth[2,1-d]isoxazole, 3a,4,5,9b-tetrahydro-3-phenyl-9b-(1-pyrrolidinyl)-7a-(1-pyrrolidinyl)-1,2-Benzisoxazole.  
 3a,4,5,6,7,7a-hexahydro-5-methyl-3-phenyl-7a-(1-pyrrolidinyl)-7007-75-2, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-(m-nitrophenyl)-7a-(1-pyrrolidinyl)-  
 (preparation of)  
 RN 7007-73-0 CAPLUS  
 CN Naphth[2,1-d]isoxazole,  
 3a,4,5,9b-tetrahydro-3-phenyl-9b-(1-pyrrolidinyl)-


L10 ANSWER 57 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (7CI, 8CI) (CA INDEX NAME)




RN 7007-74-1 CAPLUS  
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-5-methyl-3-phenyl-7a-(1-pyrrolidinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 7007-75-2 CAPLUS  
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-(m-nitrophenyl)-7a-(1-pyrrolidinyl)- (7CI, 8CI) (CA INDEX NAME)



L10 ANSWER 58 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1964:418213 CAPLUS  
 DOCUMENT NUMBER: 61:18213  
 ORIGINAL REFERENCE NO.: 61:3089c-e  
 TITLE: Enamines as 1,3-dipolarophiles  
 AUTHOR(S): Kuehne, Martin E.; Weaver, J.; Franz, Peter  
 CORPORATE SOURCE: Univ. of Vermont, Burlington  
 SOURCE: Journal of Organic Chemistry (1964), 29(6), 1582-6  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 OTHER SOURCE(S): CASREACT 61:18213  
 GI For diagram(s), see printed CA Issue.  
 AB The reactions of benzhydromoxymethyl chloride and N1-α-chlorobenzylidene-N2-phenylhydrazine with cyclic and acyclic enamines led to aminohydriodisoxazoles e.g. I, and a pyrrolidinodihydropyrazole (II). Elimination of the tertiary amine from the substituted heterocycles gave the corresponding isoxazoles, e.g. III; tetrahydriodisoxazoles, e.g. IV, were obtained directly, except in the case of the reaction leading first to II. Pyrazoles were also obtained.  
 IT 95867-96-2, 2-Isoxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)-97847-70-6, 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)-98563-49-6, 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)-  
 (preparation of)  
 RN 95867-96-2 CAPLUS  
 CN 2-isoxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)




RN 97847-70-6 CAPLUS  
 CN 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)- (7CI, 9CI) (CA INDEX NAME)



RN 98563-49-6 CAPLUS  
 CN 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)


L10 ANSWER 58 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1964:418212 CAPLUS  
DOCUMENT NUMBER: 61:18212  
ORIGINAL REFERENCE NO.: 61:30884-h,3089-a  
TITLE: 2,2'-Diacarbamoyl-5,5'-dinitrotriphenyl disulfides and  
6-nitro-1,2-benzenothiazolones  
AUTHOR(S): Ponci, R.; Gialdi, F.; Baruffini, A.  
CORPORATE SOURCE: Univ. Pavia, Italy  
SOURCE: Farmaco, Edizione Scientifica (1964), 19(3), 254-68  
CODEN: FRPSX; ISSN: 0430-0920  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
OTHER SOURCE(S): CASREACT 61:18212  
GI For diagram(s), see printed CA Issue.  
AB A solution of 16 g. 2-thiocyanato-4-nitrobenzoic acid (prepared from  
4-nitroanthranilic acid by the Sandmeyer reaction) in 300 ml. 20% KOH was  
kept on a water bath gradually heated during 30 min. to 90°, heated  
30 min. at 90°, cooled, acidified with concentrated HCl, and chilled to  
precipitate yellow 2-mercapto-4-nitrobenzoic acid (I); S-benzyl  
derivative, yellow,  
m. 197-9° (dilute EtOH, C6H6). To the moist I dissolved in hot EtOH  
was added an equal volume cold EtOH and half volume 10% H2SO4, the  
mixture  
treated dropwise with 5% iodine-EtOH to complete oxidation an equal  
volume dilute

volume dilute H<sub>2</sub>SO<sub>4</sub> added, and the whole chilled 24 hrs., filtered off, and the solid washed with EtOH, Et<sub>2</sub>O, and petr. ether to give 70% 2,2'-dicarboxy-5,5'-dinitrodiphenyl disulfide (III), yellow, m. 280°-2° (glacial AcOH). To a suspension of 20 g. dry II in 140 ml. anhydrous C<sub>6</sub>H<sub>6</sub>, 25 g. PC15 was added, the mixture refluxed 1 hr., decolorized with C, filtered, 4 vols. petr. ether added, the mixture kept a long time at 0°, filtered off, and the solid washed with petr. ether and crystallized from C<sub>6</sub>H<sub>6</sub>-petr. ether to yield 2,2'-dicarboxy-5,5'-dinitrodiphenyl disulfide dichloride (III'), yellow, m. 170°-1°. III (2.16 g.) in min. cold dioxane was added dropwise to a solution of 2 ml. concentrated NH<sub>3</sub> in 13 ml. dioxane, the mixture kept 15 min. at room temperature, 3 vols. H<sub>2</sub>O added, the mixture neutralized with AcOH, and the precipitate filtered off, and washed with H<sub>2</sub>O, then EtOH and Et<sub>2</sub>O to yield 2,2'-dicarbamoyl-5,5'-dinitrodiphenyl disulfide (IV), yellow, m. 265°-6° (AcOH). III analogously treated with BuNH<sub>2</sub> and PHNHNH<sub>2</sub> yielded, resp., 2,2'-bis(N-butylcarbamoyl)-5,5'-dinitrodiphenyl disulfide (V) pale yellow, m. 227°-9° (AcOH), and 2,2'-dicarbamino-5,5'-dinitrodiphenyl disulfide (VI), pale yellow, m. 270°-1° (PhNO<sub>2</sub>). Through a suspension of 4.3 g. III in 60 ml. anhydrous CC<sub>14</sub> containing 0.2 g. iodine, anhydrous Cl was bubbled to complete dissoln., excess Cl removed by bubbling dry air, the solution, containing 4,2-O<sub>2</sub>N(Cl)C<sub>6</sub>H<sub>3</sub>COCl (VII), added dropwise, with stirring and cooling, to 12 ml. 20% aqueous NH<sub>3</sub>, the mixture kept 2 hrs. at room temperature, the precipitate filtered off, washed with petr. ether, and suspended in a little H<sub>2</sub>O, the mixture acidified with dilute HCl, and the precipitate filtered off and washed with H<sub>2</sub>O to yield 6-nitro-1,2-benzoisothiazolone (VIII), yellow, m. 280° (EtOH) (decomposition). VII (from 4.3 g. III) in anhydrous CC<sub>14</sub> was added dropwise to a solution of 5 g. BuNH<sub>2</sub> in 20 ml.


L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 94803-44-8 CAPLUS  
CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)-  
(7CI, 9CI) (CA INDEX NAME)



RN 95867-96-2 CAPLUS  
CN 2-Isoxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)



RN 97847-70-6 CAPLUS  
CN 4-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl) - (7CI, 9CI) (CA INDEX NAME)




RN 98563-49-6 CAPLUS  
CN 4-Hydrocyclohept[disoxazolo, 3a,5,6,7,8,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)

L10 ANSWER 59 OF 60. CAPLUS. COPYRIGHT 2005 ACS ON STN (Continued)  
 anhyd. CC14, the mixt. kept 1 hr., filtered, and the filtrate evapd. in  
 vacuo at 40° to yield 2-butyl-6-nitro-1,2-benzisothiazolone (IX),  
 yellow, m. 109-10° (C6H6-ligroine). VII analogously treated with  
 PhNH2 yielded 2-phenyl-6-nitro-1,2-benzisothiazolone (X), yellow, m.  
 229-31° (PhMe). VIII (1 g.) suspended in 10 ml. AcOH, 3 ml. 30%  
 H2O2 added, and the mixt. heated on a water bath 1 hr. at 100° and  
 evapd. to dryness in vacuo at 40°, yielded 6-nitro-1,2-  
 benzisothiazolone 1,1-dioxide m. 208-9° (H2O). In the same way IX  
 yielded 2-butyl-6-nitro-1,2-benzisothiazolone 1,1-dioxide, m. 96-7°  
 (70% EtOH), and X yielded 2-phenyl-6-nitro-1,2-benzisothiazolone  
 1,1-dioxide (XI), m. 193° (dil. EtOH). Dry pulverized VIII (2 g.)  
 in 10 ml. AcOH was heated on a water bath 1 hr. at 100°, cooled, 5  
 vols. H2O added, and the ppt. filtered off and washed with H2O to yield  
 2-acetyl-6-nitro-1,2-benzisothiazolone, yellow, m. 220-2° (MeCO).  
 VIII (2 g.) treated in the same way with 10 ml. (EtCO)20, gave  
 2-propenyl-6-nitro-1,2-benzisothiazolone, yellow, m. 185-6°  
 (CHCl3). VIII in 10% alc. suspension was treated, with stirring and  
 warming at 50° with an equimolar amt. 4N NaOH to give VIII Na salt,  
 2 g. of which was suspended in 30 ml. anhyd. C6H6, 1.3 g. BzCl added, the  
 mixt. refluxed with stirring 1 hr., evapd. to dryness, and worked up to  
 yield 2-benzyl-6-nitro-1,2-benzisothiazolone, yellow, m. 154-6°  
 (PhMe). V, IX, and X inhibited the growth of Trichophyton mentagrophytes  
 at a concn. of 0.5 y.m./ml. 7 references.

IT 92647-93-2 2-isoxazoline 4-ethyl-3-phenyl-5-(1-pyrrolidinyl)-


IT 92647-93-3. 2-Isoxazoline, 4-ethyl-3-phenyl-5-(1-pyrrolidinyl)-  
 93947-42-3. 1,2-Benzisoxazole, 3a, 4, 5, 6, 7, 7a-hexahydro-7-methyl-3-  
 phenyl-7a-(1-pyrrolidinyl)- 98403-44-8. 1,2-Benzisoxazole,  
 3a, 4, 5, 6, 7, 7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl) 95867-96-2  
 , 2-Isoxazoline, 3, 4, 5-triphenyl-5-(1-pyrrolidinyl)- 97847-70-6,  
 4H-Cyclohept[di]isoazole, 3a, 5, 6, 6a-tetrahydro-3-phenyl-6a-(1-  
 pyrrolidinyl), 98563-49-6, 4H-Cyclohept[di]isoazole,  
 3a, 5, 6, 7, 8, 8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)-  
 (preparation of)  
 RN 92647-93-3 CAPLUS  
 CN 2-Isoxazoline, 4-ethyl-3-phenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX  
 NAME)

NAME)



RN 93947-42-3 CAPLUS  
CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-7-methyl-3-phenyl-7a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)

L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



ACCESSION NUMBER: 1964:82853 CAPLUS

DOCUMENT NUMBER: 60:82853

ORIGINAL REFERENCE NO.: 60:14501e-h

TITLE: Enamines. X. Reactions of halo hydroxamic acids with enamines of alicyclic compounds

AUTHOR(S): Bianchetti, Giuseppe; Pocar, Donato; Dalla Croce, Piero

CORPORATE SOURCE: Univ. Milan  
Gazzetta Chimica Italiana (1963), 93(12), 1726-35  
CODEN: GCITA9; ISSN: 0016-5603

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 60:82853

AB 1-(N-morpholinyl)-1-cycloheptene, b13 134°, was prepared by azeotropic removal of H<sub>2</sub>O from equimolar ams. of cycloheptanone and morpholine in PhMe containing a trace of MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H, followed by distillation.Similarly was prepared 1-(N-4-methylpiperazinyl)-1-cyclopentene, b0.15 116-18°. Equimolar ams. of II, 1-(N-morpholinyl)-1-cyclohexene, and Et<sub>3</sub>N boiled in CHCl<sub>3</sub> 1 hr. and evaporated to an oil that solidified gave V(R = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, n = 4, R' = N-morpholinyl), m. 138-40° (EtOH). Likewise, by boiling 45 min. to 1 hr. and using the resp. reagents were prepared the following derivs. of V: (R = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, R' = N-morpholinyl,n = 5), m. 180° (MeOH); (R = Ph, R' = N-pyrrolidinyl, n = 4), m. 103°; (R = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, R' = N-morpholinyl, n = 3), m. 154° (EtOH); (R = 4-CIC<sub>6</sub>H<sub>4</sub>, R' = N-morpholinyl, n = 3), m. 115° (MeOH); (R = Ph, R' = N-morpholinyl, n = 3), m. 105-6° (ligroine); (R = 4-CIC<sub>6</sub>H<sub>4</sub>, R' = N-piperidinyl, n = 3), m. 108° (EtOH); (R = 4-CIC<sub>6</sub>H<sub>4</sub>, R' = N-4-methylpiperidinyl, n = 3), m. 120° (ligroine).Also prepared was 3-(4-nitrophenyl)-3a-(N-morpholinyl)-3a,8a-dihydroindenol[1,2-d]isoxazole (in absence of Et<sub>3</sub>N), m. 238° (EtOH). Derivs. of V with n = 4 or 5 were readily hydrolyzed by 10-20% HCl to the corresponding derivs. of VI; thus were prepared: R =4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, n = 4, m. 180° (EtOH); R = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, n = 5, m. 132° (MeOH); R= Ph, n = 4, m. 50° (aqueous AcOH); however V with n = 3 were recovered unchanged even with 48% HBr. V (R = Ph, R' = N-morpholinyl, n = 4), m. 103°, was also prepared as in previous paper from benzonitrile N-oxide and 1-(N-morpholinyl)-1-cyclohexene (VII) in boiling CHCl<sub>3</sub>, 30 min. VI (R = CO<sub>2</sub>H, n = 4), m. 128° (H<sub>2</sub>O), was prepared by boiling 10 g. ClC<sub>6</sub>(NOH)(CO<sub>2</sub>Et) and VII in 300 cc. CHCl<sub>3</sub> 1 hr. and evaporating to anoil which was extracted with Et<sub>2</sub>O, filtered, evaporated, and the residue boiled 30

min. with 100 cc. 10% NaOH and then acidified.


IT 94803-44-8, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-

(1-pyrrolidinyl)-

(preparation of)

RN 94803-44-8 CAPLUS

CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)-(7CI, 9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.03	264.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-7.30

STN INTERNATIONAL LOGOFF AT 08:54:08 ON 24 OCT 2005